Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mentor’s Prevelle Silk

This article was originally published in The Gray Sheet

Executive Summary

Hyaluronic acid-based dermal filler containing the local anesthetic lidocaine for pain reduction gains FDA market go-ahead for treatment of moderate to severe facial lines, folds and wrinkles. The first in a new line of HA dermal fillers that Mentor is developing with Genzyme under an October 2006 R&D pact, Prevelle Silk will roll out "shortly" on a targeted basis to experienced dermatology and plastic surgery customers, Mentor says. A broader U.S. launch of the product is anticipated by Mentor "later this year," in conjunction with a second lidocaine-containing dermal filler which is under FDA review (1"The Gray Sheet" Nov. 6, 2006, p. 14)

You may also be interested in...



Mentor Plans Expansion Of Prevelle Dermal Filler Line, Strategic Review

New additions to Mentor's fledgling Prevelle dermal filler portfolio in the U.S. will help grow its facial aesthetic product revenue in the next several years, the company said during a Nov. 5 second-quarter earnings call

Mentor Injects Dermal Filler Pipeline With Genzyme R&D

Mentor will market future Genzyme-developed hyaluronic acid dermal filler products to complement its existing Puragen hyaluronic acid device platform under a partnership agreement announced Oct. 30

Basilea Stresses Derazantinib's FGFR Kinase Differentiation

Switzerland’s SIX exchange-listed drug development company, Basilea, is moving two new oncology candidates along its R&D pipeline, supported by strong revenues from two partnered anti-infective products.

 

UsernamePublicRestriction

Register

MT025947

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel